Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
07/27/2022* -- Results Q2 2022 -- -0.15 --
05/03/2022 -- Results Q1 2022 -0.14 -0.14 -1.95%
05/03/2022 16:30 EST Earnings Call Q1 2022 -- -- --
03/29/2022 -- Results Q4 2021 -0.13 -0.14 3.85%
03/29/2022 16:30 EST Earnings Call Q4 2021 -- -- --
11/02/2021 -- Results Q3 2021 -0.12 -0.14 13.38%
11/02/2021 16:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/27/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/03/2022
Beat/Miss Upgrade
Return Since -12.54%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.
URL https://www.infi.com
Investor Relations URL https://investors.infi.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release May. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-53.52%
-82.80%
50.37%
-41.87%
-18.64%
120.8%
6.13%
-67.35%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
66.00%
45.78%
148.8%
-26.02%
-9.43%
116.2%
-24.31%
20.20%
--
--
185.3%
50.12%
-38.72%
-45.92%
-82.26%
-66.16%
-33.00%
-25.52%
143.4%
110.0%
52.53%
364.6%
-35.65%
-54.20%
-8.85%
80.03%
-16.72%
64.96%
-4.89%
26.87%
-8.04%
-32.40%
As of June 24, 2022.

Profile

Edit
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.
URL https://www.infi.com
Investor Relations URL https://investors.infi.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release May. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter INFI Tweets